Montelukast Paediatric Bristol Laboratories (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Paediatric Bristol Laboratories, is a leukotriene receptor antagonist presented as an oral tablet for pediatric use. It is used to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in children. GNH USA supplies Montelukast Paediatric Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to control chronic respiratory conditions in children. - Asthma: improves long‑term control and reduces the frequency of asthma attacks. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergens.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: persistent dry cough. - Sore throat: irritation or pain in the throat. - Nausea: feeling of queasiness. - Diarrhoea: loose, watery stools.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling or difficulty breathing. - Stevens‑Johnson syndrome: severe skin blistering and detachment. - Angioedema: rapid swelling of face, lips or tongue. - Mood changes: depression, anxiety or suicidal thoughts. - Hepatic injury: abnormal liver function tests. - Severe hypersensitivity: anaphylaxis requiring immediate medical attention.

When prescribing Montelukast, consider the following safety measures. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Hepatic function: use with caution in patients with liver impairment. - Acute asthma attacks: not a rescue medication; provide a short‑acting bronchodilator for emergencies. - Hypersensitivity: avoid in individuals with known allergy to Montelukast or any tablet excipients. - Pediatric dosing: follow prescriber’s instructions specific to age and weight. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Montelukast plasma levels. - Phenobarbital or rifampin: potent inducers that can markedly lower Montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as Montelukast may affect anticoagulation. - Antidepressants (e.g., fluoxetine): observe for enhanced neuropsychiatric effects. - Theophylline: assess for possible additive bronchial effects. - Other leukotriene modifiers: avoid concurrent use to prevent overlapping toxicity.